Cadila gets tentative USFDA nod for Simvastatin

Cadila Healthcare has received tentative approval from the USFDA to market Simvastatin Tablets of 5 mg, 10 mg, 20 mg, 40 mg and 80mg, in the US market.

According to the release issued by the company to the BSE, the drug, a lipid lowering agent, falls in the cardiovascular segment. The branded sales of Simvastatin Tablets in the US market were estimated at $4.6 billion as per IMS (March 2006). The company will market the drug through its US subsidiary Zydus Pharmaceuticals.